What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Jan J. Cornelissen mostly deals with Internal medicine, Transplantation, Immunology, Hematopoietic stem cell transplantation and Surgery.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
His Oncology research is multidisciplinary, incorporating elements of Cancer and Nilotinib, Imatinib, Dasatinib, Imatinib mesylate.
Jan J. Cornelissen has researched Transplantation in several fields, including Chemotherapy regimen, Stem cell, Hazard ratio, Leukemia and Bone marrow.
His work carried out in the field of Leukemia brings together such families of science as Myeloid and Retrospective cohort study.
His Hematopoietic stem cell transplantation study incorporates themes from Cellular immunity, Minimal residual disease, Transplantation Conditioning, Induction chemotherapy and Acute leukemia.
His most cited work include:
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2888 citations)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
- Human fetal lymphoid tissue–inducer cells are interleukin 17–producing precursors to RORC + CD127 + natural killer–like cells (525 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Oncology and Immunology.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
His Transplantation study combines topics from a wide range of disciplines, such as Incidence, Cumulative incidence, Stem cell and Bone marrow.
His Hematopoietic stem cell transplantation research is multidisciplinary, incorporating perspectives in Survival rate, Minimal residual disease, Hazard ratio, Transplantation Conditioning and Survival analysis.
The Oncology study combines topics in areas such as Cancer, Proportional hazards model, Retrospective cohort study and Disease.
His work carried out in the field of Leukemia brings together such families of science as Myeloid, Chemotherapy regimen and Univariate analysis.
He most often published in these fields:
- Internal medicine (70.56%)
- Transplantation (60.54%)
- Hematopoietic stem cell transplantation (33.40%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (70.56%)
- Transplantation (60.54%)
- Oncology (32.99%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Myeloid leukemia.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.
His Transplantation study integrates concerns from other disciplines, such as Cyclophosphamide, Stem cell, Retrospective cohort study and Disease.
Jan J. Cornelissen has researched Oncology in several fields, including Chemotherapy, Allogeneic hct, Ibrutinib, Cumulative incidence and Human leukocyte antigen.
Jan J. Cornelissen studied Hematopoietic stem cell transplantation and Total body irradiation that intersect with Univariate analysis.
His Myeloid leukemia study deals with Sibling intersecting with Myelofibrosis.
Between 2018 and 2021, his most popular works were:
- Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants (145 citations)
- Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). (67 citations)
- Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation (46 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Myeloid leukemia are his primary areas of study.
His research integrates issues of Sibling, Regimen, Disease and Incidence in his study of Transplantation.
His Oncology research is multidisciplinary, relying on both Chemotherapy, Secondary Acute Myeloid Leukemia, Cumulative incidence, Ibrutinib and Human leukocyte antigen.
His Hematopoietic stem cell transplantation research includes themes of Family medicine, Total body irradiation, Cord blood and Acute leukemia.
His work deals with themes such as Treosulfan, Transplant Conditioning, Fludarabine and Busulfan, which intersect with Myeloid leukemia.
His Leukemia research focuses on Myeloid and how it relates to Trisomy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
